Developing new tools to design shorter antibiotic treatments for tuberculosis
Official title: BEYOND BURDEN: NEW TOOLS FOR TUBERCULOSIS ANTIBIOTICREGIMEN DESIGN
Funded at University of Colorado Denver · NIH-10816584 · Data updated 2026-11-12
This study is looking for better ways to treat tuberculosis (TB) by finding out how different antibiotics can work faster and more effectively, which could help patients get better in less time.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | April 1, 2023 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $245,619 |
| NIH project number | 5R21AI171065-02 |
| Project ID | NIH-10816584 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with tuberculosis who require antibiotic treatment.
✕Less likely to help
Patients with drug-resistant tuberculosis or those who have already completed TB treatment may not benefit from this research.
What this research studies
This research aims to address the global tuberculosis (TB) epidemic by creating new methods to shorten the treatment duration required for curing TB. It focuses on understanding how different antibiotics affect the bacteria responsible for TB, particularly how they penetrate lung lesions and target drug-tolerant populations. By evaluating the impact of these drugs on bacterial processes, the research seeks to identify more effective treatment regimens. Patients may benefit from shorter and more effective TB treatments as a result of this innovative approach.
Why it matters
Potential benefit: If successful, this research could lead to significantly shorter treatment times for tuberculosis patients, improving their quality of life and treatment adherence.
How similar studies have gone: Previous research has shown promise in developing new treatment strategies for tuberculosis, but this approach is innovative and aims to fill existing gaps in understanding drug efficacy.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Voskuil, Martin Inua — University of Colorado Denver
- Study coordinator: Voskuil, Martin Inua
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.